The cost effectiveness of treating paediatric cancer in low-income and middle-income countries: A case-study approach using acute lymphocytic leukaemia in Brazil and Burkitt lymphoma in Malawi

Archives of Disease in Childhood

Volumn 98, Issue 2, 2013, Pages 155-160

  Bhakta, Nickhill ^a   Martiniuk, Alexandra L C ^b,c,d,e   Gupta, Sumit ^f   Howard, Scott C ^g  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^d UNIVERSITY OF TORONTO   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BRAZIL; BURKITT LYMPHOMA; CANCER INCIDENCE; CANCER PATIENT; CHILD; CHILDHOOD CANCER; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISABILITY ADJUSTED LIFE YEARS; DRUG COST; EVENT FREE SURVIVAL; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HUMAN; INFANT; LOW INCOME AND MIDDLE INCOME COUNTRY; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALAWI; MULTICENTER STUDY; PATIENT SELECTION; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SOCIOECONOMICS; WORLD HEALTH ORGANIZATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; DISABILITY ADJUSTED LIFE YEAR; HEALTH CARE POLICY; QUALITY ADJUSTED LIFE YEAR;

ADOLESCENT; BRAZIL; BURKITT LYMPHOMA; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HEALTH CARE COSTS; HUMANS; INCOME; INFANT; LEUKEMIA, LYMPHOID; MALAWI; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT;

EID: 84872674486     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2011-301419     Document Type: Article

References (41)

1. Ferlay J, Shin H-R, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Pui C-H, Campana D, Pei D, et al. Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation. N Engl J Med 2009;360:2730-41.
3. Molyneux EME, Rochford RR, Griffin BB, et al. Burkitt's lymphoma. The Lancet 2012;379:1234-44.
4. Davidoff AM. Wilms' tumor. Curr Opin Pediatr 2009;21:357-64.
5. Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 2009;27:2308-18.
6. Howard SC, Metzger ML, Wilimas JA, et al. Childhood cancer epidemiology in low-income countries. Cancer 2008;112:461-72. (Pubitemid 351186186)
7. Ribeiro RC, Steliarova-Foucher E, Magrath I, et al. Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study. Lancet Oncol 2008;9:721-9. (Pubitemid 352038313)
8. Farmer P, Frenk J, Knaul FM, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet 2010;376:1186-93.
9. Ginsberg GMG, Lauer JAJ, Zelle SS, et al. Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ 2012;344:e614.
10. Ginsberg GM, Lim SS, Lauer JA, et al. Prevention, screening and treatment of colorectal cancer: a global and regional generalized cost effectiveness analysis. Cost Effectiveness and Resource Allocation 2010;8:2.
11. Ginsberg GM, Edejer TT-T, Lauer JA, et al. Screening, prevention and treatment of cervical cancer - a global and regional generalized cost-effectiveness analysis. Vaccine 2009;27:6060-79.
12. Groot MT, Baltussen R, Uyl-de Groot CA, et al. Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia. Breast J 2006;12(Suppl 1):S81 -90.
13. Mellstedt H. Cancer initiatives in developing countries. Ann Oncol 2006;17(Suppl 8):viii24-31.
14. Ribeiro RC, Pui C-H. Saving the children - improving childhood cancer treatment in developing countries. N Engl J Med 2005;352:2158-60. (Pubitemid 40727081)
15. Soderstrom L, Woods WG, Bernstein M, et al. Health and economic benefits of well-designed evaluations: some lessons from evaluating neuroblastoma screening. J Natl Cancer Inst 2005;97:1118-24. (Pubitemid 41511210)
16. van Litsenburg RRL, Uyl-de Groot CA, Raat H, et al. Cost-effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: the influence of new medication and diagnostic technology. Pediatr Blood Cancer 2011;57:1005-10.
17. Rahiala J, Riikonen P, Kekäläinen L, et al. Cost analysis of the treatment of acute childhood lymphocytic leukaemia according to Nordic protocols. Acta Paediatr 2000;89:482-7. (Pubitemid 30636832)
18. Jamison DT, Bank W. Disease control priorities in developing countries. 2nd edn. USA: Oxford University Press, 2006. http://www.dcp2.org/pubs/DCP (accessed 6 Jul 2012).
19. Murray Lopez C, Jamison ADDT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ 1994;72:495.
20. World Health Organization. The Global Burden of Disease: 2004 Update. World Health Organization, 2008. http://www.who.int/healthinfo/global-burden- disease/GBD-report-2004update-full.pdf (accessed 6 Jul 2012).
21. The World Factbook. Central Intelligence Agency. https://www.cia.gov/ library/publications/the-world-factbook/ (accessed 6 Jul 2012).
22. Mathers C, Fat DM World Health Organization. Global Burden of Disease 2004 Update: Disability Weights for Diseases and Conditions. 2008.
23. Acharya A, Adam T, Baltussen R., et al. Making choices in health: WHO guide to cost-effectiveness analysis. World Health Organization, 2003. http://www.who.int/choice/publications/p-2003-generalised-cea.pdf (accessed 6 Jul 2012).
24. Xie Y, Davies SM, Xiang Y, et al. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 2003;97:2229-35. (Pubitemid 36444065)
25. Howard SC. Establishment of a Pediatric Oncology Program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA 2004;291:2471-5. (Pubitemid 38669191)
26. Hesseling P, Molyneux E, Kamiza S, et al. Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate. Ann Trop Paediatr 2009;29:29-34.
27. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001;93:618-29. (Pubitemid 32409629)
28. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001;19:3163-72. (Pubitemid 32591432)
29. Patte C, Auperin A, Michon J, et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97:3370-9.
30. Hesseling PB. Burkitt lymphoma treatment: the Malawi experience. J Afr Cancer 2009;1:72-9.
31. Masera G. Bridging the childhood cancer mortality gap between economically developed and low-income countries. J Pediatr Hematol Oncol 2009;31:710-12.
32. Valsecchi MG, Steliarova-Foucher E. Cancer registration in developing countries: luxury or necessity? Lancet Oncol 2008;9:159-67. (Pubitemid 351150127)
33. Pui C-H, Ribeiro RC. International collaboration on childhood leukemia. Int J Hematol 2003;78:383-9. (Pubitemid 37549617)
34. Howard SC, Marinoni M, Castillo L, et al. Improving outcomes for children with cancer in low-income countries in Latin America: A report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO)-Part I. Pediatr Blood Cancer 2007;48:364-9. (Pubitemid 46238534)
35. Mostert S, Arora RS, Arreola M, et al. Abandonment of treatment for childhood cancer: position statement of a SIOP PODC Working Group. Lancet Oncol 2011;12:719-20.
36. Mostert S, Sitaresmi MN, Gundy CM, et al. Comparing childhood leukaemia treatment before and after the introduction of a parental education programme in Indonesia. Arch Dis Child 2010;95:20-5.
37. Bonilla M, Gupta S, Vasquez R, et al. Predictors of outcome and methodological issues in children with acute lymphoblastic leukaemia in El Salvador. Eur J Cancer 2010;46:3280-6.
38. Tang Y, Xu X, Song H, et al. Long-term outcome of childhood acute lymphoblastic leukemia treated in China. Pediatr Blood Cancer 2008;51:380-6.
39. Brandalise SR, Pinheiro VR, Aguiar SS, et al. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group - protocol ALL-99. J Clin Oncol 2010;28:1911-18.
40. Sandlund JT, Fonseca TT, Leimig TT, et al. Predominance and characteristics of Burkitt lymphoma among children with nonHodgkin lymphoma in northeastern Brazil. Leukemia 1997;11:743-6. (Pubitemid 27241256)
41. Madani A, Zafad S, Harif M, et al. Treatment of Wilms tumor according to SIOP 9 protocol in Casablanca, Morocco. Pediatr Blood Cancer 2006;46:472-5. (Pubitemid 43334654)